[{"id":"5b878eb7-4cec-43f6-8253-c1aa01df90b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351909","created_at":"2021-01-18T05:31:32.481Z","updated_at":"2024-07-02T16:35:15.320Z","phase":"Phase 1","brief_title":"Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT01351909","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA1 mutation • HER-2 negative • PGR positive • BRCA mutation • PARP1 expression","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HER-2 negative • PGR positive • BRCA mutation • PARP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/02/2011","start_date":" 05/02/2011","primary_txt":" Primary completion: 11/25/2016","primary_completion_date":" 11/25/2016","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"bdd3367d-e70f-45d7-a591-4ecb156f7478","acronym":"","url":"https://clinicaltrials.gov/study/NCT04221061","created_at":"2021-03-26T11:04:32.655Z","updated_at":"2024-07-02T16:35:36.252Z","phase":"Phase 1","brief_title":"18F-FluorThanatrace (PET/CT) in Glioblastoma","source_id_and_acronym":"NCT04221061","lead_sponsor":"University of Pennsylvania","biomarkers":" HRD","pipe":" | ","alterations":" HRD • PARP1 expression","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • PARP1 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-09-21"},{"id":"0e12a744-e7c9-4313-8eb9-b9c47df253d7","acronym":"AGO-TR 1","url":"https://clinicaltrials.gov/study/NCT02222883","created_at":"2021-01-18T10:25:07.110Z","updated_at":"2024-07-02T16:36:29.019Z","phase":"","brief_title":"Prevalence of BRCA in Patients With Ovarian Cancer","source_id_and_acronym":"NCT02222883 - AGO-TR 1","lead_sponsor":"AGO Research GmbH","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" PARP1 expression","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PARP1 expression"],"overall_status":"Completed","enrollment":" Enrollment 530","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2021-06-16"}]